Literature DB >> 26152288

Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast.

Ashraf Dallol1,2, Abdelbaset Buhmeida3, Adnan Merdad4, Jaudah Al-Maghrabi5, Mamdooh A Gari3,6, Muhammad M Abu-Elmagd3,7, Aisha Elaimi8,6, Mourad Assidi3, Adeel G Chaudhary3,6, Adel M Abuzenadah3,8,6, Taoufik Nedjadi9, Eramah Ermiah10, Shadi S Alkhayyat11, Mohammed H Al-Qahtani3,6.   

Abstract

Invasive ductal carcinoma of the breast is the most common cancer affecting women worldwide. The marked heterogeneity of breast cancer is matched only with the heterogeneity in its associated or causative factors. Breast cancer in Saudi Arabia is apparently an early onset with many of the affected females diagnosed before they reach the age of 50 years. One possible rationale underlying this observation is that consanguinity, which is widely spread in the Saudi community, is causing the accumulation of yet undetermined cancer susceptibility mutations. Another factor could be the accumulation of epigenetic aberrations caused by the shift toward a Western-like lifestyle in the past two decades. In order to shed some light into the molecular mechanisms underlying breast cancer in the Saudi community, we identified KLOTHO (KL) as a tumor-specific methylated gene using genome-wide methylation analysis of primary breast tumors utilizing the MBD-seq approach. KL methylation was frequent as it was detected in 55.3 % of breast cancer cases from Saudi Arabia (n = 179) using MethyLight assay. Furthermore, KL is downregulated in breast tumors with its expression induced following treatment with 5-azacytidine. The involvement of KL in breast cancer led us to investigate its relationship in the context of breast cancer, with one of the protagonists of its function, fibroblast growth factor receptor 4 (FGFR4). Overexpression of FGFR4 in breast cancer is frequent in our cohort and this overexpression is associated with poor overall survival. Interestingly, FGFR4 expression is higher in the absence of KL methylation and lower when KL is methylated and presumably silenced, which is suggestive of an intricate relationship between the two factors. In conclusion, our findings further implicate "metabolic" genes or pathways in breast cancer that are disrupted by epigenetic mechanisms and could provide new avenues for understanding this disease in a new context.

Entities:  

Keywords:  Breast cancer; FGF19; FGFR4; KLOTHO; Methylation

Mesh:

Substances:

Year:  2015        PMID: 26152288     DOI: 10.1007/s13277-015-3733-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  Klotho is silenced through promoter hypermethylation in gastric cancer.

Authors:  Liangjing Wang; Xian Wang; Xiaojia Wang; Pan Jie; Haiqi Lu; Shengjie Zhang; Xiaoying Lin; Emily Ky Lam; Yan Cui; Jun Yu; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2010-11-10       Impact factor: 6.166

2.  α-Klotho protects against oxidative damage in pulmonary epithelia.

Authors:  Priya Ravikumar; Jianfeng Ye; Jianning Zhang; Sydney N Pinch; Ming Chang Hu; Makoto Kuro-o; Connie C W Hsia; Orson W Moe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-07-25       Impact factor: 5.464

3.  Regulation of multiple ageing-like phenotypes by inducible klotho gene expression in klotho mutant mice.

Authors:  Hiroaki Masuda; Hirotaka Chikuda; Tatsuo Suga; Hiroshi Kawaguchi; Makoto Kuro-o
Journal:  Mech Ageing Dev       Date:  2005-09-06       Impact factor: 5.432

4.  FGFR4 Arg388 genotype is associated with pathological complete response to neoadjuvant chemotherapy for primary breast cancer.

Authors:  F Marmé; W Werft; A Benner; B Burwinkel; P Sinn; C Sohn; P Lichter; M Hahn; A Schneeweiss
Journal:  Ann Oncol       Date:  2010-02-10       Impact factor: 32.976

Review 5.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

6.  Epigenetic silencing of the tumor suppressor klotho in human breast cancer.

Authors:  Tami Rubinek; Michal Shulman; Shira Israeli; Shikha Bose; Ayelet Avraham; Adi Zundelevich; Ella Evron; Einav Nili Gal-Yam; Bella Kaufman; Ido Wolf
Journal:  Breast Cancer Res Treat       Date:  2011-10-22       Impact factor: 4.872

7.  PeakAnalyzer: genome-wide annotation of chromatin binding and modification loci.

Authors:  Mali Salmon-Divon; Heidi Dvinge; Kairi Tammoja; Paul Bertone
Journal:  BMC Bioinformatics       Date:  2010-08-06       Impact factor: 3.169

8.  The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma.

Authors:  Jaehyouk Lee; Dong-Jun Jeong; Jinsun Kim; Soonduck Lee; Jin-Hwa Park; Boogi Chang; Sam-Il Jung; Lisha Yi; Youngsoo Han; Young Yang; Keun Il Kim; Jong-Seok Lim; Inchul Yang; Seob Jeon; Dong Han Bae; Chang-Jin Kim; Myeong-Sok Lee
Journal:  Mol Cancer       Date:  2010-05-18       Impact factor: 27.401

9.  Epigenetic silencing of Klotho expression correlates with poor prognosis of human hepatocellular carcinoma.

Authors:  Biao Xie; Jianping Zhou; Lianwen Yuan; Feng Ren; Dong-cai Liu; Qinglong Li; Guoshun Shu
Journal:  Hum Pathol       Date:  2012-10-31       Impact factor: 3.466

10.  High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.

Authors:  Abdelbaset Buhmeida; Ashraf Dallol; Adnan Merdad; Jaudah Al-Maghrabi; Mamdooh A Gari; Muhammad M Abu-Elmagd; Adeel G Chaudhary; Adel M Abuzenadah; Taoufik Nedjadi; Eramah Ermiah; Fatima Al-Thubaity; Mohammed H Al-Qahtani
Journal:  Tumour Biol       Date:  2013-11-19
View more
  9 in total

Review 1.  FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Authors:  Kevin M Levine; Kai Ding; Lyuqin Chen; Steffi Oesterreich
Journal:  Pharmacol Ther       Date:  2020-05-31       Impact factor: 12.310

2.  Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma.

Authors:  Abeer A Alsofyani; Rawiah A Alsiary; Alaa Samkari; Baraa T Alhaj-Hussain; Jalaluddin Azam Khan; Jaudah Al-Maghrabi; Aisha Elaimi; Mohammed H Al-Qahtani; Adel M Abuzenadah; Ashraf Dallol
Journal:  J Appl Genet       Date:  2017-08-16       Impact factor: 3.240

3.  Enhancement of Pathologist's Routine Practice: Reuse of DNA Extracted from Immunostained Formalin-fixed Paraffin-embedded (FFPE) Slides in Downstream Molecular Analysis of Cancer.

Authors:  Asmaa Al-Attas; Mourad Assidi; Jaudah Al-Maghrabi; Ashraf Dallol; Hans-Juergen Schulten; Muhammad Abu-Elmagd; Adeel Chaudhary; Adel Abuzenadah; Bruce Budowle; Abdelbaset Buhmeida; Mohammed Al-Qahtani
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

4.  Klotho negatively regulated aerobic glycolysis in colorectal cancer via ERK/HIF1α axis.

Authors:  Qingguo Li; Yaqi Li; Lei Liang; Jing Li; Dakui Luo; Qi Liu; Sanjun Cai; Xinxiang Li
Journal:  Cell Commun Signal       Date:  2018-06-08       Impact factor: 5.712

Review 5.  Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies.

Authors:  Liwei Lang; Yong Teng
Journal:  Cells       Date:  2019-01-09       Impact factor: 6.600

Review 6.  Fibroblast growth factor receptor signalling dysregulation and targeting in breast cancer.

Authors:  Chiara Francavilla; Ciara S O'Brien
Journal:  Open Biol       Date:  2022-02-23       Impact factor: 6.411

7.  Klotho promoter methylation status and its prognostic value in ovarian cancer.

Authors:  Maryam H Al-Zahrani; Fatimah M Yahya; Mourad Assidi; Ashraf Dallol; Abdelbaset Buhmeida
Journal:  Mol Clin Oncol       Date:  2021-07-03

8.  Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.

Authors:  Kai Hung Tiong; Boon Shing Tan; Heng Lungh Choo; Felicia Fei-Lei Chung; Ling-Wei Hii; Si Hoey Tan; Nelson Tze Woei Khor; Shew Fung Wong; Sze-Jia See; Yuen-Fen Tan; Rozita Rosli; Soon-Keng Cheong; Chee-Onn Leong
Journal:  Oncotarget       Date:  2016-09-06

Review 9.  Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.

Authors:  Yanan Liu; Meng Cao; Yuepiao Cai; Xiaokun Li; Chengguang Zhao; Ri Cui
Journal:  Front Cell Dev Biol       Date:  2020-02-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.